Description of the Award
The overall goal is to understand the molecular hematopoietic events that mediate progression of myeloid malignancies from pre-leukemic, or early stage myeloid disorders, such as myelodysplastic syndromes or myeloproliferative neoplasms, to frank hematologic malignancy that could lead to novel therapeutics to control such disease progression. Proposal topics of interest might include, but are not limited to:
- Identify the molecular, cellular and epigenetic drivers of progression to leukemia
- Identify the role of the immune system in progression from molecular alteration to full blown leukemia
- Understand the role of the microenvironment in enabling disease progression
- Develop predictive preclinical models to assess disease progression
- Develop immunologic and/or molecular monitoring approaches
- Develop treatment strategies and/or approaches for early interception (vaccines, nutraceuticals, drugs...etc.)
This RFP represents an innovative LLS research grant paradigm; TCI projects should, if successful, have a measurable impact on the diagnosis or treatment of patients with hematologic malignancies over the next 5 to 10 years by intercepting myeloid malignancies prior to disease progression. Proposals must include specific timelines, milestones and deliverables that researchers believe are achievable with their proposed funding. The funding available is $400,000 total over a period of 3 years.
Additional funding for projects that have demonstrated exceptional progress in the initial 3 years may be available, subject to review by LLS and by continued support by Janssen. Additional funding is not guaranteed for any of the projects, and is contingent on the achievement of the project goals. The LLS Research Department staff will work with researchers to monitor progress and provide insight and expertise to each project.
Both LLS and Janssen are committed to supporting early stage, foundational research as well as new therapy development.
Special Considerations for Grantees and their Institutions:
In addition to LLS's standard terms and conditions for academic grant awards, TCI also includes the following requirements. As part of the sponsorship agreement with Janssen, academic institutions and researchers will have to agree that LLS can prepare and provide research updates once a year via a confidential project summary to Janssen. Each applicant to the TCI is required to have his or her Institution certify agreement with LLS's IP terms and participation in the Transforming CURES Initiative at the time of application submission. For questions regarding this policy please contact Research Administration.
Application Process and Deadlines
The applicant and Sponsoring Institution must register independently with the LLS Research Portal site powered by FLUXX in order for applicant to apply. Timelines and deadlines for the application process are shown below.
To apply please visit FLUXX by visiting the following url: http://lls.fluxx.io
|Call for Propoals||October 2014|
|Letter of Intent Deadline||January 15, 2015||3:00 PM ET|
|Full Application Deadline||February 27, 2015||3:00 PM ET|
|Scientific Peer Review Committee||May 2015|
|Notification of Awards||June 2015|
|Anticipated Funding Start Date||October 2015|
For additional questions regarding LLS grant programs, eligibility and application processes, please contact the Director of Research Administration at firstname.lastname@example.org .